Wanbury Launches Four New Anesthetic APIs at Tanuku

Wanbury Limited announces launch of four new anesthetic APIs at its Tanuku facility, targeting ₹100 crore revenue in FY 2026-27, expected to add 15% to company's annual revenue.

Wanbury Limited Reports Strong Q2 FY26 Performance with 20% EBITDA Growth

Wanbury Limited achieved EBITDA of ₹26.0 crore (16.2% margin) in Q2 FY26 compared to ₹21.6 crore (13.3% margin) in Q2 FY25, marking 20% growth driven by enhanced product yields and procurement efficiencies. The pharmaceutical company's PAT surged 89% to ₹15.2 crore from ₹8.0 crore year-over-year, with formulations business turning EBITDA positive and successful launch of new iron supplement brand C-red.

Wanbury Limited Posts Strong Q2 FY26 Results with 20% EBITDA Growth and 90% PAT Surge

Wanbury Limited reported robust quarterly results with EBITDA rising 20% to ₹26 crore (16.2% margin) and PAT jumping 89% to ₹15.2 crore, driven by enhanced product yields, procurement efficiencies, and lower finance costs. The pharmaceutical company's formulations business turned EBITDA positive while API business maintained strong performance, with management highlighting successful digital transformation and commitment to sustainable growth through new product launches.